 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Patient Screening Completed in Part 2 of Phase 1b/2a Trial of BX004 with patient enrollment expected to exceed original estimates FDA grants BX004 Fast Track designation Initial Data from Part 2 Now Expected in November 2023 Company Will Host a Conference Call and Webcast Today at 8:00 am ET ...

BiomX Reports Second Quarter 2023 Financial Results and Provides Business Update

Shares of the Companys common stock and units (PHGE and PHGE.U) are unaffected by delisting proceedings of warrants and will remain trading on NYSE AmericanCAMBRIDGE, Mass. and NESS ZIONA, Israel, June 08, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (BiomX or the Company), a clinical-...

NYSE American Initiates Delisting Proceedings for BiomX Warrants

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 31, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (BiomX or the Company), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will present ...

BiomX to Present Part 1 Data from Phase 1b/2a Study Evaluating BX004 for the Treatment of Chronic Pseudomonas aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session at the 46th European Cystic Fibrosis Confer

Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis (CF); Results from Part 2 Expected in Third Quarter of 2023 Second and Final Closing of PIPE Investment Completed, Raising Total Gross Proceeds of $7.5 million; Cash ...

BiomX Reports First Quarter 2023 Financial Results and Provides Business Update

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (BiomX or the Company), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointments of Jason M. ...

BiomX Announces the Appointments of Jason M. Marks and Michael E. Dambach to Board of Directors

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 08, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (BiomX or the Company), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a ...

BiomX to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 15th, 2023

CAMBRIDGE, Mass. and NESS ZIONA, Israel, May 05, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (BiomX or the Company), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the second closing of its ...

BiomX Announces Second Closing of $7.5 Million Private Placement

Announced Positive Results from Part 1 of Ongoing Phase 1b/2a Trial of BX004 for Treatment of Lung Infections in Cystic Fibrosis (CF) Patient Enrollment Continues in Part 2 of Phase 1b/2a Trial with Results Expected in Third Quarter of 2023 Cash Runway Through at Least Mid-2024 Company Will Host a ...

BiomX Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 27, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (BiomX or the Company), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a ...

BiomX to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on March 29th, 2023

CAMBRIDGE, Mass. and NESS ZIONA, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (BiomX or the Company), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a ...

BiomX Announces $7.5 Million Private Placement

BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Ness Ziona, Israel.

Watchers	763
52-Wk Low	$0.132
52-Wk High	$0.69

Market Cap	$13.37M
Volume (M)	44,089.00
52-Wk High	$0.69
52-Wk Low	$0.132

PHGE BiomX Inc

About

Feed

News

Sentiment

Earnings

Fundamentals